Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:BSTG NASDAQ:BTCY NASDAQ:CTSO NASDAQ:EDAP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBSTGBiostage$4.45$4.45$4.45▼$4.45$61.78M-1.021,847 shsN/ABTCYBiotricity$0.58+7.2%$0.46$0.19▼$0.83$14.42M1.1237,894 shs13,718 shsCTSOCytosorbents$0.95+0.7%$1.02$0.71▼$1.61$59.21M1.28141,984 shs48,197 shsEDAPEdap Tms$2.76+22.1%$1.53$1.21▼$3.77$84.51M-0.21129,222 shs415,909 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBSTGBiostage0.00%0.00%0.00%0.00%0.00%BTCYBiotricity0.00%-17.29%+40.26%+13.78%+30.30%CTSOCytosorbents0.00%+4.09%+8.54%-5.66%-10.15%EDAPEdap Tms0.00%+64.96%+73.39%+25.91%-37.57%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBSTGBiostageN/AN/AN/AN/AN/AN/AN/AN/ABTCYBiotricityN/AN/AN/AN/AN/AN/AN/AN/ACTSOCytosorbents2.0994 of 5 stars3.32.00.00.03.70.00.6EDAPEdap Tms2.4516 of 5 stars3.23.00.00.02.51.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBSTGBiostage 0.00N/AN/AN/ABTCYBiotricity 2.00HoldN/AN/ACTSOCytosorbents 2.50Moderate Buy$5.50478.83% UpsideEDAPEdap Tms 2.33Hold$8.50207.97% UpsideCurrent Analyst Ratings BreakdownLatest BTCY, EDAP, BSTG, and CTSO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/20/2025CTSOCytosorbentsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.008/8/2025CTSOCytosorbentsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.007/21/2025CTSOCytosorbentsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.006/25/2025CTSOCytosorbentsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00(Data available from 9/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBSTGBiostageN/AN/AN/AN/A($0.26) per shareN/ABTCYBiotricity$12.06M1.20N/AN/A($1.30) per share-0.45CTSOCytosorbents$35.60M1.68N/AN/A$0.18 per share5.28EDAPEdap Tms$63.02M1.64N/AN/A$1.18 per share2.34Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBSTGBiostage-$6.07M-$0.58N/A∞N/AN/AN/A-174.43%N/ABTCYBiotricity-$14.09M-$0.21N/A∞N/A-80.42%N/A-188.47%11/13/2025 (Estimated)CTSOCytosorbents-$20.72M-$0.17N/AN/AN/A-25.58%-111.97%-29.00%11/6/2025 (Estimated)EDAPEdap Tms-$20.58M-$0.61N/AN/AN/A-33.49%-56.85%-26.83%11/5/2025 (Estimated)Latest BTCY, EDAP, BSTG, and CTSO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025CTSOCytosorbents-$0.07-$0.05+$0.02$0.03$9.79 million$9.62 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBSTGBiostageN/AN/AN/AN/AN/ABTCYBiotricityN/AN/AN/AN/AN/ACTSOCytosorbentsN/AN/AN/AN/AN/AEDAPEdap TmsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBSTGBiostageN/A2.732.73BTCYBiotricityN/A0.230.10CTSOCytosorbents1.242.341.96EDAPEdap Tms0.041.511.21Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBSTGBiostageN/ABTCYBiotricity3.89%CTSOCytosorbents32.87%EDAPEdap Tms62.74%Insider OwnershipCompanyInsider OwnershipBSTGBiostage15.30%BTCYBiotricity10.10%CTSOCytosorbents6.60%EDAPEdap Tms0.23%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBSTGBiostage713.88 million11.76 millionNot OptionableBTCYBiotricity4024.91 million22.08 millionOptionableCTSOCytosorbents22062.76 million58.62 millionOptionableEDAPEdap Tms23037.39 million37.31 millionOptionableBTCY, EDAP, BSTG, and CTSO HeadlinesRecent News About These CompaniesFY2029 EPS Estimates for EDAP TMS Lowered by HC WainwrightSeptember 2 at 2:19 AM | marketbeat.comFY2029 EPS Estimates for Edap Tms Cut by HC WainwrightSeptember 2 at 2:57 AM | americanbankingnews.comEDAP TMS (NASDAQ:EDAP) Releases Quarterly Earnings ResultsAugust 30 at 8:20 AM | marketbeat.comEdap Tms S.a. (NASDAQ:EDAP) Q2 2025 Earnings Call TranscriptAugust 29, 2025 | insidermonkey.comEDAP TMS S.A. (EDAP) Q2 2025 Earnings Conference Call TranscriptAugust 28, 2025 | seekingalpha.comWhat's Next: Edap TMS's Earnings PreviewAugust 28, 2025 | benzinga.comEDAP TMS S.A. reports Q2 resultsAugust 28, 2025 | seekingalpha.comEDAP Reports Strong Second Quarter 2025 HIFU ResultsAugust 28, 2025 | globenewswire.comEDAP TMS S.A. Q2 2025 Earnings PreviewAugust 27, 2025 | msn.comEdap TMS SA (EDAP) Q2 2025: Everything You Need To Know Ahead Of EarningsAugust 27, 2025 | finance.yahoo.comEDAP executes letter of intent for €36M financing from European Investment BankAugust 26, 2025 | msn.comEDAP TMS enters LOI for EUR 36M credit facilityAugust 26, 2025 | msn.comEDAP Announces Letter of Intent for 36 Million Euro Credit Facility to Accelerate Growth and Strategic ExpansionAugust 26, 2025 | globenewswire.comEDAP TMS SA CEO Ryan Rhodes to Speak at H.C. Wainwright 27th Annual Global Investment ConferenceAugust 25, 2025 | quiverquant.comQEDAP to Participate in the H.C. Wainwright 27th Annual Global Investment ConferenceAugust 25, 2025 | globenewswire.comEdap Tms (EDAP) to Release Earnings on ThursdayAugust 23, 2025 | marketbeat.comEdap Tms S.A. (NASDAQ:EDAP) Short Interest UpdateAugust 20, 2025 | marketbeat.comThe past three years for EDAP TMS (NASDAQ:EDAP) investors has not been profitableAugust 14, 2025 | finance.yahoo.comEDAP to Announce Second Quarter 2025 Financial Results on August 28, 2025August 7, 2025 | globenewswire.comEDAP TMS S.A. (EDAP) Latest Stock News & Headlines - Yahoo FinanceJuly 1, 2025 | finance.yahoo.comEDAP Announces Transition from Foreign Private Issuer to U.S. Domestic Filer StatusJuly 1, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBTCY, EDAP, BSTG, and CTSO Company DescriptionsBiostage OTCMKTS:BSTG$4.45 0.00 (0.00%) As of 07/24/2023Biostage, Inc., a biotechnology company, offers products to cure patients of cancers, injuries, and birth defects of the gastro-intestinal tract and the airways. The company's pipeline includes organ-regeneration technology for the repair or replacement of diseased or damaged organs, as well as product candidates to treat cancer, injury, and birth defects of the bronchus. Its lead product candidate is Biostage Esophageal Implant for the treatment of severe esophageal disease. The company was formerly known as Harvard Apparatus Regenerative Technology, Inc. and changed its name to Biostage, Inc. in March 2016. Biostage, Inc. was founded in 2009 and is headquartered in Holliston, Massachusetts.Biotricity NASDAQ:BTCY$0.58 +0.04 (+7.22%) As of 02:37 PM EasternBiotricity, Inc., a medical technology company, provides biometric data monitoring solutions in the United States. The company focuses on delivery of remote monitoring solutions to medical, healthcare, and consumer markets, including diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses. It offers Bioflux mobile cardiac telemetry solution, an integrated ECG device; and ECG analysis software that analyzes and synthesizes patient ECG monitoring data, as well as software components. The company is based in Redwood City, California.Cytosorbents NASDAQ:CTSO$0.95 +0.01 (+0.72%) Closing price 04:00 PM EasternExtended Trading$0.96 +0.01 (+1.03%) As of 05:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals. The company also develops CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, and removal of anti-A and anti-B blood group antibodies from whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it develops BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove drugs and chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.Edap Tms NASDAQ:EDAP$2.76 +0.50 (+22.12%) Closing price 04:00 PM EasternExtended Trading$2.76 +0.01 (+0.18%) As of 07:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.EDAP TMS SA is a holding company, which, through its subsidiary, engages in the development, production, and marketing of minimally invasive medical devices for urological diseases. It operates through the High Intensity Focused Ultrasound (HIFU) and Urology Devices and Services (UDS) segments. The HIFU segment develops, manufactures, and markets devices for the minimally invasive ablation of certain types of localized tumors using HIFU technology. The UDS segment focuses on the development, marketing, manufacturing, and servicing of medical devices for the minimally invasive diagnosis or treatment of urological disorders, mainly urinary stones, and other clinical indications. The company was founded on December 3, 1979 and is headquartered in Vaulx-en-Velin, France. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas CrowdStrike Tests $412 Support as Options Traders Turn Bullish Loop Industries Insiders Buy Stock, Signal Confidence in Outlook Joby Aviation's Pullback: A Gift for Investors Who See the Future Kohl’s Stock Rebound Faces a Showdown With Short Sellers Amazon Faces Rare Downgrade—Is the Rally at Risk? What to Watch for From D-Wave Now That Earnings Are Done Alibaba Rallies on New AI Chip Design, Sending NVIDIA Stock Lower 3 High-Yield Stocks Just Supercharged Their Dividends Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
